JosephAnthonyTreatMD

Oncology • Philadelphia, PA

Physician

Join to view full profile

Dr. Treat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Treat's full profile

Already have an account?

Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111
Phone+1 215-728-6900

Fax+1 215-214-1425

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1984
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1979 - 1982
Lewis Katz School of Medicine at Temple UniversityClass of 1979

Certifications & Licensure

PA State Medical License 1988 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC Start of enrollment: 2019 Sep 04
Recruiting
Phase 2

Publications & Presentations

PubMed

Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort.
J Nicholas Bodor, Joanne Xiu, Vinicius Ernani, Supreet Kaur, Hirva Mamdani
Clinical Lung Cancer. 2024-11-01
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Har...
J Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, Benjamin P Levy, Hossein Borghaei
Clinical Lung Cancer. 2023-11-01
1 citations
Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
Sandra V Fernandez, Yin Fei Tan, Shilpa Rao, Patricia Fittipaldi, Fathima Sheriff
International Journal of Molecular Sciences. 2023-10-30

Press Mentions

Lantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 9th, 2024